Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

797 ARTÍCULOS , VIENDO DEL 676 AL 690

Clinical definition, biological characterization, and detection guidelines of subjective cognitive decline due to Alzheimer's disease and related dementia: A position paper from ISTAART SCD PIA

Moretti DV, Kuhn E, Dubbelmann MA, Sikkes SAM, Castilhos RM, Chapman S, Gifford KA, Butterbrod E, Nosheny RL; Subjective Cognitive Decline Professional Interest Area, Alzheimer's Association ISTAART.

Alzheimers Dement. 2025 Dec;21(12):e70847. doi: 10.1002/alz.70847.

A phase 2A/B randomized trial of metabolic modulators intranasal insulin and empagliflozin for MCI and early AD

Erichsen JM, Register TC, Sutphen C, Ma D, Gaussoin SA, Rudolph M, Rundle M, Bateman JT, Lockhart SN, Sai KKS, Whitlow C, Craft S.

Alzheimers Dement. 2025 Oct;21(10):e70704. doi: 10.1002/alz.70704.

Boston University Alzheimer's Disease Research Center Clinical Core: Infrastructure to facilitate research on post-traumatic Alzheimer's disease and related dementias

Alosco ML, Morrison M, Au R, Steinberg EG, Mwicigi J, Ly M, Altaras C, Lenio S, Abdennadher M, O'Connor MK, Tripodis Y, Palmisano J, Dixon D, Martin B, Schneider G, Groh JR, Ellison A, Sheppard D, Farris CW, Nowinski C, Cantu RC, Turk KW, Farrer L, Jun G, Goldstein LE, Qiu WQ, Stein TD, Budson AE, McKee AC, Mez J.

Alzheimers Dement. 2025 Sep;21(9):e70654. doi: 10.1002/alz.70654.

Unraveling the Role of Autotaxin and Lysophosphatidic Acid in Alzheimer's Disease: From Molecular Mechanisms to Therapeutic Potential

García-de Soto J, Castro-Mosquera M, Pouso-Diz JM, Fernández-Cabrera A, Rodríguez-Arrizabalaga M, Debasa-Mouce M, Camino-Castiñeiras J, Minguillón Pereiro AM, Aramburu-Núñez M, Romaus-Sanjurjo D, Aldrey JM, Pego-Reigosa R, Pías-Peleteiro JM, Sobrino T, Ouro A.

Int J Mol Sci. 2025 Jul 23;26(15):7068. doi: 10.3390/ijms26157068.

Successes and failures: the latest advances in the clinical development of amyloid-β-targeting monoclonal antibodies for treating Alzheimer's disease

Panza F, Dibello V, Sardone R, Zupo R, Castellana F, Leccisotti I, Moretti MC, Altamura M, Bellomo A, Daniele A, Solfrizzi V, Resta E, Lozupone M.

Expert Opin Biol Ther. 2025 Mar;25(3):275-283. doi: 10.1080/14712598.2025.2463963. Epub 2025 Feb 7.

Combining CSF MTBR-tau243 and plasma pTau217 ratio enhances the prediction of continuous regional tau PET burden in early Alzheimer's disease

Devanarayan V, Horie K, Wildsmith K, Doherty T, Andreozzi E, Charil A, Sachdev P, Kramer LD, Dhadda S, Irizarry MC.

Alzheimers Dement. 2025 Nov;21(11):e70881. doi: 10.1002/alz.70881.

Unmasking a Paradox: Roles of the PD-1/PD-L1 Axis in Alzheimer's Disease-Associated Neuroinflammation

Moadab A, Khorramdelazad H, Javar MTA, Nejad MSM, Mirzaie S, Hatami S, Mahdavi N, Ghaffari S, Yazdian FA.

J Neuroimmune Pharmacol. 2025 Apr 26;20(1):46. doi: 10.1007/s11481-025-10206-5.

Exosomes in Alzheimer's disease: From pathogenesis to therapeutics-A comprehensive review of diagnostic and drug delivery applications

Shahlaei M, Afkhami H, Ahmadieh-Yazdi A, Mirmazloumi SH, Sahraei SS, Akbari M, Yang P, Manoochehri H, Tanzadehpanah H, Mahaki H, Sundararaman A, Mohan S, Sheykhhasan M, Al-Musawi S, Dama P.

Biomed Pharmacother. 2025 Nov;192:118548. doi: 10.1016/j.biopha.2025.118548. Epub 2025 Sep 22.

Targeting Transferrin Receptor 1 for Enhancing Drug Delivery Through the Blood-Brain Barrier for Alzheimer's Disease

Shen X, Li H, Zhang B, Li Y, Zhu Z.

Int J Mol Sci. 2025 Oct 8;26(19):9793. doi: 10.3390/ijms26199793.

Precision diagnosis of cognitive impairment due to Alzheimer's disease for therapeutic interventions

Knopman DS.

Alzheimers Dement. 2025 Jan;21(1):e14043. doi: 10.1002/alz.14043. Epub 2024 Dec 24.

A phase 2 randomized, placebo-controlled study on the efficacy and safety of AR1001, a phosphodiesterase-5 inhibitor, in patients with mild-to-moderate Alzheimer's disease

Greeley D, Nash M, Herskowitz B, Kim F, Rock J, Prins N, Kim S, Xi T, Busam JA, Tete B, Choung JJ, Sha SJ.

J Prev Alzheimers Dis. 2025 Nov;12(9):100337. doi: 10.1016/j.tjpad.2025.100337. Epub 2025 Sep 5.

Alzheimer's Disease Clinical Trials: What Have We Learned From Magnetic Resonance Imaging

By S, Kahl A, Cogswell PM.

J Magn Reson Imaging. 2025 Feb;61(2):579-594. doi: 10.1002/jmri.29462. Epub 2024 Jun 20.

[Differential diagnosis of Alzheimer's disease and vascular cognitive disorders]

Cherdak MA, Mkhitaryan EA, Tkacheva ON.

Zh Nevrol Psikhiatr Im S S Korsakova. 2025;125(4. Vyp. 2):26-35. doi: 10.17116/jnevro202512504226.

Cutting through the noise: A narrative review of Alzheimer's disease plasma biomarkers for routine clinical use

Schöll M, Vrillon A, Ikeuchi T, Quevenco FC, Iaccarino L, Vasileva-Metodiev SZ, Burnham SC, Hendrix J, Epelbaum S, Zetterberg H, Palmqvist S.

J Prev Alzheimers Dis. 2025 Apr;12(4):100056. doi: 10.1016/j.tjpad.2024.100056. Epub 2025 Jan 14.

The role of exosomes in diagnosis, pathophysiology, and management of Alzheimer's Disease

Daksh R, Mathew MS, Bosco AM, Sojan C, Tom AA, Bojja SL, Nampoothiri M.

Biochem Biophys Res Commun. 2025 Mar 25;754:151526. doi: 10.1016/j.bbrc.2025.151526. Epub 2025 Feb 21.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias